Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Res. 2019 Mar 20;79(7):1438–1450. doi: 10.1158/0008-5472.CAN-18-1220

Figure 6: Reduced sensitivity to mTOR inhibition in CRISPR/Cas9 targeted 4E-BP1 HNSCC cells in vivo.

Figure 6:

(A) Cal33 control and 4E-BP1 CCT cells were transplanted into athymic nude mice and treated by INK128. (Data are the mean ±SEM of the tumor volume; ***P < .001 when compared with the control-treated group, n = 10 per group). (B) Representative histological sections from each treatment group in panel A. Scale bars represent 1 mm. (C-D) Representative immunohistochemical analysis of pS6 (C) and p4E-BP1(D) in tumors from panel A. (E) Representative immunohistochemical analysis and quantification of Ki67 (left) and cleaved-Caspase 3 to determine the percentage of apoptotic cells (right) in tumors from panel A.